{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T06:38:04Z","timestamp":1774766284922,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The management of Alzheimer's disease (AD) poses considerable challenges, necessitating the pursuit of innovative therapeutic approaches. Recent research has spotlighted the promising role of phosphodiesterase type 5 inhibitors (PDE5Is) in reducing the prevalence of AD, utilizing their vasodilatory properties to suggest a potential neuroprotective effect. This meta-analysis and systematic review aims to assess the relationship between the use of PDE5Is and the risk of AD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A detailed examination was carried out across several electronic databases till March 2024, including PubMed, Web of Science, Scopus, CENTRAL, and Embase. The focus was on identifying studies that compare the occurrence of AD among PDE5I users vs non-users. Through a random-effects model, pooled hazard ratios (HRs) were calculated, in alignment with guidelines from the Cochrane Handbook for Systematic Reviews and Meta-Analysis and the PRISMA standards.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This analysis included six studies, cumulating a participant count of 8,337,313, involving individuals treated with sildenafil, tadalafil, and vardenafil, against a control group undergoing other or no treatments. The cumulative HR for AD risk among PDE5I users versus the control group was 0.53 (95% CI: 0.32\u20130.86, p\u2009=\u20090.008), signaling a markedly reduced likelihood of AD development in the PDE5I group. Particularly, sildenafil usage showed a significant risk reduction (HR: 0.46, 95% CI: 0.31\u20130.70, p\u2009&lt;\u20090.001), while findings for tadalafil and vardenafil were not significant. Test of subgroup differences found no difference between male and female participants in the risk of AD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest that the use of PDE5Is is associated with a reduced risk of AD, highlighting its potential as a protective agent against neurodegenerative diseases. Given the very low quality of evidence and the heterogeneity among the included studies, further high-quality research is warranted to confirm these findings and elucidate the underlying mechanisms. Register number PROSPERO 2024: CRD42024522197.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10072-024-07583-9","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T06:02:04Z","timestamp":1716616924000},"page":"5261-5270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Phosphodiesterase-5 inhibitors use and the risk of alzheimer's disease: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0511-2429","authenticated-orcid":false,"given":"Moaz Elsayed","family":"Abouelmagd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4703-4203","authenticated-orcid":false,"given":"Maickel","family":"Abdelmeseh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5592-3908","authenticated-orcid":false,"given":"Amr","family":"Elrosasy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3303-7737","authenticated-orcid":false,"given":"Yousef Hesham","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-4289","authenticated-orcid":false,"given":"Asmaa Zakria","family":"Alnajjar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2255-7454","authenticated-orcid":false,"given":"Mahmoud","family":"Eid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3393-9105","authenticated-orcid":false,"given":"Atef","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5101-5972","authenticated-orcid":false,"given":"Abdallah","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"key":"7583_CR1","doi-asserted-by":"publisher","unstructured":"Alzheimer\u2019s Association (2023) 2023 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 19(4):1598\u20131695. https:\/\/doi.org\/10.1002\/alz.13016","DOI":"10.1002\/alz.13016"},{"issue":"2","key":"7583_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5937\/zdravzast50-32931","volume":"50","author":"J Gruji\u010di\u0107","year":"2021","unstructured":"Gruji\u010di\u0107 J, Nikoli\u0107 A (2021) Alzheimers disease: Epidemiological characteristics and prevention. Zdr Zastita 50(2):57\u201372. https:\/\/doi.org\/10.5937\/zdravzast50-32931","journal-title":"Zdr Zastita"},{"issue":"7","key":"7583_CR3","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1080\/13803395.2020.1798882","volume":"42","author":"A Roquet","year":"2020","unstructured":"Roquet A, Michel BF, Lemaire P (2020) Alzheimer\u2019s disease disrupts domain-specific and domain-general processes in numerosity estimation. J Clin Exp Neuropsychol 42(7):690\u2013709. https:\/\/doi.org\/10.1080\/13803395.2020.1798882","journal-title":"J Clin Exp Neuropsychol"},{"issue":"1","key":"7583_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/WNN.0000000000000225","volume":"33","author":"J Macoir","year":"2020","unstructured":"Macoir J, Lafay A, Hudon C (2020) The impairment of number transcoding abilities in individuals with amnestic mild cognitive impairment and alzheimer disease: associations with attentional and executive functions. Cogn Behav Neurol 33(1):33\u201344. https:\/\/doi.org\/10.1097\/WNN.0000000000000225","journal-title":"Cogn Behav Neurol"},{"key":"7583_CR5","doi-asserted-by":"publisher","unstructured":"Jain MS, Koradia SK (2023) Phosphodiesterase-5 (PDE5) inhibitors in the treatment of erectile dysfunction: a review. Asian J Pharm Res 13(1):63\u201367. https:\/\/doi.org\/10.52711\/2231-5691.2023.00012","DOI":"10.52711\/2231-5691.2023.00012"},{"issue":"3","key":"7583_CR6","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/0976500X221129008","volume":"13","author":"Q Saikia","year":"2022","unstructured":"Saikia Q, Hazarika A, Mishra R (2022) A review on the pharmacological importance of PDE5 and its inhibition to manage biomedical conditions. J Pharmacol Pharmacother 13(3):246\u2013257. https:\/\/doi.org\/10.1177\/0976500X221129008","journal-title":"J Pharmacol Pharmacother"},{"issue":"5","key":"7583_CR7","doi-asserted-by":"publisher","first-page":"fcac260","DOI":"10.1093\/braincomms\/fcac260","volume":"4","author":"D Newby","year":"2022","unstructured":"Newby D (2022) Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer\u2019s disease and related dementias? Brain Commun 4(5):fcac260. https:\/\/doi.org\/10.1093\/braincomms\/fcac260","journal-title":"Brain Commun"},{"issue":"4","key":"7583_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.52403\/ijshr.20221023","volume":"7","author":"S Kumar","year":"2022","unstructured":"Kumar S, Kulshreshtha DRM, Saha S (2022) Contribution of Phosphodiesterase-5 (PDE5) inhibitors in the various diseases. Int J Sci Healthc Res 7(4):164\u2013172. https:\/\/doi.org\/10.52403\/ijshr.20221023","journal-title":"Int J Sci Healthc Res"},{"key":"7583_CR9","doi-asserted-by":"publisher","first-page":"121570","DOI":"10.1016\/j.lfs.2023.121570","volume":"320","author":"AFO Justo","year":"2023","unstructured":"Justo AFO, Toscano ECDB, Farias-Itao DS, Suemoto CK (2023) The action of phosphodiesterase-5 inhibitors on \u03b2-amyloid pathology and cognition in experimental Alzheimer\u2019s disease: A systematic review. Life Sci 320:121570. https:\/\/doi.org\/10.1016\/j.lfs.2023.121570","journal-title":"Life Sci"},{"issue":"12","key":"7583_CR10","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/alz.12559","volume":"18","author":"MMH Pauls","year":"2022","unstructured":"Pauls MMH, Binnie LR, Benjamin P et al (2022) The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment. Alzheimers Dement 18(12):2393\u20132402. https:\/\/doi.org\/10.1002\/alz.12559","journal-title":"Alzheimers Dement"},{"issue":"1","key":"7583_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3233\/ADR-200166","volume":"4","author":"O Sanders","year":"2020","unstructured":"Sanders O (2020) Sildenafil for the Treatment of Alzheimer\u2019s Disease: A Systematic Review. J Alzheimers Dis Rep 4(1):91\u2013106. https:\/\/doi.org\/10.3233\/ADR-200166","journal-title":"J Alzheimers Dis Rep"},{"key":"7583_CR12","doi-asserted-by":"publisher","unstructured":"Sanders O, Rajagopal L (2020) Phosphodiesterase inhibitors for alzheimer's disease: a systematic review of clinical trials and epidemiology with a mechanistic rationale. J Alzheimers Dis Rep 4(1):185\u2013215. Published 2020 Jun 16. https:\/\/doi.org\/10.3233\/ADR-200191","DOI":"10.3233\/ADR-200191"},{"key":"7583_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan \u2014 a web and mobile app for systematic reviews. Syst Rev 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"7583_CR14","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Retrieved from http:\/\/www.ohrica\/programs\/clinical_epidemi"},{"key":"7583_CR15","unstructured":"Viswanathan M, Ansari MT, Berkman ND, Chang S, Hartling L, McPheeters LM (2012) Assessing the risk of bias of individual studies in systematic reviews of health care interventions. Agency for Healthcare Research and Quality Methods Guide for Comparative Effectiveness Reviews. March 2012. AHRQ Publication No. 12-EHC047-EF. Retrieved from https:\/\/effectivehealthcare.ahrq.gov\/"},{"key":"7583_CR16","unstructured":"Sch\u00fcnemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH (2022) Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane.\u00a0Available from https:\/\/www.training.cochrane.org\/handbook"},{"issue":"3","key":"7583_CR17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1136\/jech-2021-217090","volume":"76","author":"T Wilkinson","year":"2022","unstructured":"Wilkinson T, Schnier C, Bush K, Rannikm\u00e4e K, Lyons RA, McTaggart S et al (2022) Drug prescriptions and dementia incidence: a medication-wide association study of 17000 dementia cases among half a million participants. J Epidemiol Commun Health 76(3):223\u2013229","journal-title":"J Epidemiol Commun Health"},{"issue":"10","key":"7583_CR18","doi-asserted-by":"publisher","first-page":"e0292863","DOI":"10.1371\/journal.pone.0292863","volume":"18","author":"DS Henry","year":"2023","unstructured":"Henry DS, Pellegrino RG (2023) A case-control study of phosphodiesterase-5 inhibitor use and Alzheimer\u2019s disease and related dementias among male and female patients aged 65 years and older supporting the need for a phase III clinical trial. Silman I, editor. PLoS One 18(10):e0292863","journal-title":"PLoS One"},{"issue":"12","key":"7583_CR19","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/s43587-021-00138-z","volume":"1","author":"J Fang","year":"2021","unstructured":"Fang J, Zhang P, Zhou Y, Chiang CW, Tan J, Hou Y et al (2021) Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer\u2019s disease. Nat Aging 1(12):1175\u20131188","journal-title":"Nat Aging"},{"key":"7583_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.urology.2023.08.021","volume":"182","author":"AE Braun","year":"2023","unstructured":"Braun AE, Cowan JE, Hampson LA, Broering JM, Suskind AM, Carroll PR (2023) Association between common urologic medications and onset of alzheimer\u2019s disease and related dementias in men with prostate cancer managed by different primary treatment modalities. Urology 182:161\u2013167","journal-title":"Urology"},{"issue":"4","key":"7583_CR21","doi-asserted-by":"publisher","first-page":"e2091","DOI":"10.1212\/WNL.0000000000209131","volume":"102","author":"M Adesuyan","year":"2024","unstructured":"Adesuyan M, Jani YH, Alsugeir D et al (2024) Phosphodiesterase type 5 inhibitors in men with erectile dysfunction and the risk of alzheimer disease: a cohort study. Neurology 102(4):e2091\u2013e2311. https:\/\/doi.org\/10.1212\/WNL.0000000000209131","journal-title":"Neurology"},{"key":"7583_CR22","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3233\/SHTI230291","volume":"302","author":"X Huo","year":"2023","unstructured":"Huo X, Finkelstein J (2023) Using big data to uncover association between sildenafil use and reduced risk of Alzheimer\u2019s disease. Stud Health Technol Inform 302:866\u2013870. https:\/\/doi.org\/10.3233\/SHTI230291","journal-title":"Stud Health Technol Inform"},{"key":"7583_CR23","doi-asserted-by":"publisher","first-page":"112004","DOI":"10.1016\/j.bbr.2019.112004","volume":"372","author":"W El-Bakly","year":"2019","unstructured":"El-Bakly W, Wagdy O, Sobhy A et al (2019) The efficacy and underlying mechanism of phosphodiesterase- 5 inhibitors in preventing cognitive impairment and Alzheimer pathology: A systematic review of animal studies. Behav Brain Res 372:112004. https:\/\/doi.org\/10.1016\/j.bbr.2019.112004","journal-title":"Behav Brain Res"},{"issue":"7","key":"7583_CR24","first-page":"407","volume":"38","author":"SA Huang","year":"2013","unstructured":"Huang SA, Lie JD (2013) Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. P T 38(7):407\u2013419","journal-title":"P T"},{"key":"7583_CR25","doi-asserted-by":"publisher","unstructured":"Giannetta E, Feola T, Gianfrilli D et al (2014) Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med 12(1). https:\/\/doi.org\/10.1186\/s12916-014-0185-3","DOI":"10.1186\/s12916-014-0185-3"},{"issue":"2","key":"7583_CR26","first-page":"265","volume":"14","author":"S Gur","year":"2013","unstructured":"Gur S, Kadowitz PJ, Gokce A, Sikka SC, Lokman U, Hellstrom WJ (2013) Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension. Curr Drug Metab 14(2):265\u2013269","journal-title":"Curr Drug Metab"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07583-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07583-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07583-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T04:04:06Z","timestamp":1728705846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07583-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["7583"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07583-9","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,25]]},"assertion":[{"value":"30 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Moaz Abouelmagd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"Informed consent and Ethical approval were not sought for this paper because it included no direct interaction with human participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent and ethical approval"}},{"value":"The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}